Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LGMN | Q99538 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278981 | 0.92 | LGMN (0.54) | MAPTALDH1A1LGMNGSK3BL3MBTL1 | |
| SCHEMBL17278980 | 0.87 | CA12 (0.41) | MAPTALDH1A1LGMNAKR1C3THRB | |
| SCHEMBL17279007 | 0.85 | MAPT (0.45) | MAPTALDH1A1LGMNADRA2AADRA2B | |
| SCHEMBL19823017 | 0.81 | CA12 (0.44) | MAPTALDH1A1LGMNAKR1C3THRB | |
| SCHEMBL17278983 | 0.78 | GSK3B (0.51) | MAPTALDH1A1LGMNGSK3BL3MBTL1 | |
| SCHEMBL23084182 | 0.76 | S1PR1 (0.44) | MAPTALDH1A1LGMNL3MBTL1L3MBTL3 | |
| SCHEMBL19850678 | 0.75 | MEN1 (0.41) | MAPTALDH1A1ADRA2AADRA2BADRA2C | |
| SCHEMBL19844460 | 0.75 | ADRB1 (0.41) | MAPTALDH1A1LGMNAKR1C3L3MBTL1 | |
| SCHEMBL17786666 | 0.75 | MAPT (0.37) | MAPTALDH1A1LGMNADRA2AADRA2B | |
| SCHEMBL17786665 | 0.75 | MAPT (0.37) | MAPTALDH1A1LGMNADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9644148-B2 | Liquid Crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9644148-B2 | Liquid Crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150337203-A1 | COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20150337203-A1 | COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337203-A1 | COMPOSITION | CRY1, CRY2, C5 | MAPT 120/4885ALDH1A1 3469/4885LGMN 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.